The contribution of EAF P5K6 Alb as therapeutic to modify the severity of SCD is through supra plasma expander activity, which facilitates improved tissue oxygenation, and can be considered an anti-anemia therapeutic benefit [52]. This evidence concerns the gene ALB and anemia (phenotype).